期刊文献+

A randomized,controlled trial of Shutangluo fang in treating painful diabetic peripheral neuropathy

A randomized,controlled trial of Shutangluo fang in treating painful diabetic peripheral neuropathy
下载PDF
导出
摘要 OBJECTIVE:To assess efficacy of Shutangluo fang on painful diabetic peripheral neuropathy(PDPN).METHODS:Adopting stratified randomized and controlled design,82 patients with PDPN were assigned to two groups.Both groups continued conventional therapy.Epalrestat was administered to patients in both groups,and Shutangluo fang was given to patients in the treatment group.The treatment course lasted for 3 months.The changes before and after treatment of symptoms and signs,electrophysiological assessments were observed.RESULTS:The efficacy of the treatment group was better than the control group.The sensory nerve conduction velocity was significantly improved in the treatment group than the control group.CONCLUSIONS:Shutangluo fang is effective on PDPN. OBJECTIVE: To assess efficacy of Shutangluo fang on painful diabetic peripheral neuropathy(PDPN) METHODS: Adopting stratified randomized and controlled design, 82 patients with PDPN were assigned to two groups Both groups continued conventional therapy. Epalrestat was administered to patients in both groups, and Shutangluo fang was given to patients in the treatment group. The treatment course lasted for 3 months. The changes before and after treatment of symptoms and signs, electrophysiological assessments were observed RESULTS: The efficacy of the treatment group was better than the control group. The sensory nerve conduction velocity was significantly improved in the treatment group than the control group. CONCLUSIONS: Shutangluo fang is effective on PDPN
出处 《World Journal of Integrated Traditional and Western Medicine》 2016年第3期4-7,共4页 世界中西医结合杂志(英文)
关键词 Painful diabetic peripheral neuropathy Shutangluo fang EPALRESTAT 糖尿病 神经病变 治疗方法 临床分析
  • 相关文献

参考文献2

二级参考文献18

  • 1廖二元 超楚生.内分泌学[M].北京:人民卫生出版社,2001.610-611.
  • 2庞国明.第七次全国中医糖尿病学术大会[M].南宁:中华中医药学会,2003:64-65.
  • 3Tesfaye S, Boulton A J, Dyek PJ, et al. Diabetic neuropathies : update on definitions, diagnostic criteria, estimation of severity, and treatments [ J ]. Diabetes Care, 2010,33 ( 10 ) :2285-2293.
  • 4Diabetes Control and Complications Trial Research Group : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [ J ]. N Engl J Med, 1993,329(14) :977-986.
  • 5Greene DA, Sima AA, Stevens MJ, et al. Complications: neuropathy, pathogenetic considerations [ J ]. Diabetes Care, 1992,15 (12) : 1902- 1925.
  • 6Schemmela KE, Padiyarab RS, D' Souzab JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review [J]. J Diabetes Complications, 2010,24(5) :354-360.
  • 7Yaqub BA, Siddique A, Sulimani R. Effects of methylcobalamin on diabetic neuropathy [ J ]. Clin Neurol Neurosurg, 1992,94 ( 2 ) : 105- 111.
  • 8Vinik AI, Mehrabyan A. Diabetic neuropathies [ J ]. Med Clin North Am, 2004,88(4) :947-999.
  • 9Oates PJ. Polyol pathway and diabetic peripheral neuropathy [ J ]. Int Rev Neurobiol, 2002,50 ( 1 ) : 325-392.
  • 10Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy : a 52-week multicenter placebo-controlled double-blind parallel group study [ J ]. Diabetes Care, 2001,24 (10) : 1776-1782.

共引文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部